Virios Therapeutics Says Phase 2b Study Of IMC-1 In Fibromyalgia Fails To Meet Primary Endpoint
(RTTNews) - Virios Therapeutics, Inc. (VIRI), a development-stage biotechnology company focused on chronic diseases, including fibromyalgia or FM,...
Source: businessinsider.com